Novartis Drug Pluvicto Cuts Prostate Cancer Progression Risk by 28% in Major Trial
Novartis said its cancer drug Pluvicto has reduced the risk of disease progression or death by 28% in men with an advanced form of prostate cancer. The findings come from a large Phase III clinical trial. The study focused on men with PSMA-positive metastatic hormone-sensitive prostate cancer. These patients received Pluvicto along with standard hormone-based…